Bing

SEARCH HISTORY

TrovaGene (NASDAQ:TROV)‘s stock had its “buy” rating reissued by analysts at Cantor Fitzgerald in a research report issued to clients and investors on Friday, Market Beat reports. They currently have a $14.00 target price on the stock. Cantor ...
wkrb13.com · 7 hours ago
TrovaGene (NASDAQ:TROV)‘s stock had its “buy” rating reaffirmed by investment analysts at Cantor Fitzgerald in a note issued to investors on Friday, Marketbeat reports. They currently have a $14.00 price objective on the stock. Cantor Fitzgerald’s ...
Ticker Report · 19 hours ago
Cantor Fitzgerald
In-depth coverage >
One stock that might be an intriguing choice for investors right now is TrovaGene, Inc. (TROV). This is because this security in the Biotechnology space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank ...
Yahoo Finance · 9/4/2014
More from Bing News
A stock is considered to be oversold if the RSI reading falls below 30. In trading on Friday, shares of TrovaGene Inc (TROV) entered into oversold territory, hitting an RSI reading of 29.7, after changing hands as low as $8.
The Street · 6/26/2015
The companies are Methode Electronics Inc. (NYSE:MEI), World Acceptance Corp. (NASDAQ:WRLD), and TrovaGene Inc (NASDAQ:TROV). Let’s start with Methode ... one of the funds to close a position in the …
INSIDER MONKEY · 6/26/2015
Hedge Funds
Axovant Sciences Ltd (AXON) has posted a new high of 31.17 above a previous 52 week high of –. The company traded at $29.99 + 14.99 (99.93 pct.) on 10,449,193 total stock volume. Atlanticus Holdings Corporation …
Fx Pips · 6/12/2015
total stock volume
Shares of TrovaGene (NASDAQ:TROV) have earned a consensus broker rating score of 1.00 (Strong Buy) from the four brokers that cover the stock, Zacks Investment Research reports. Four research analysts have rated the stock with a strong buy rating.
Mideast Times · 6/21/2015
TROV) – the San Diego-based “liquid-biopsy” play we first recommended back on March 11 – have sold off sharply in the past week. That’s not a surprise. In our initial report, we classified TrovaGene as an …
Money Morning · 6/29/2015
It is worth noting however that TROV is still up around 112% from the start of the year and there are multiple upcoming catalysts that could continue to drive the stock higher. However, a key support level for TROV was breached on its most recent move lower.
Stockhouse · 6/26/2015
TrovaGene Inc (TROV - Snapshot Report) has been on the move lately as the stock has risen by 11.1% in the past four weeks, and it is currently trading well above its 20-Day SMA. This is a pretty solid move higher, but the question that has to be on ...
ZACKS · 6/11/2015